Omnix Medical Advances New Anti-Infective Program into Clinical Development | Proteins and Peptides

Omnix Medical Advances Novel Anti-Infective Program Through Clinical Development

– Entirely new therapeutic principle to combat the alarming global rise in antimicrobial resistance (AMR)

JERUSALEM, Israel I March 16, 2022 I Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that it has received approval from Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy volunteers. The trial will take place in Groningen, the Netherlands.

OMN6, Omnix’s lead compound, is a first-in-class antimicrobial peptide for the treatment of life-threatening infections caused by Gram-negative bacteria. In 2017, OMN6 was designated as a Qualified Infectious Disease Product (QIDP) by the US FDA. In 2020, Omnix secured over €10 million in clinical development funding for OMN6 from the European Innovation Committee (EIC) H2020, with the program ranked at the top percentile. In 2021, the US National Institutes of Health (NIH) awarded a grant for the development of OMN6 targeting Acinetobacter baumannii (A. baumannii) infections, joining the Israeli Innovation Authority (IIA) which funds the activities of Omnix Medical since its inception.

OMN6 will be evaluated in a randomized, double-blind, placebo-controlled, single-escalating-dose trial evaluating the safety, tolerability, and pharmacokinetics of a single and repeated IV infusion of OMN6 in healthy subjects. Results are expected in the fourth quarter of 2022.

Based on preclinical development results, OMN6 has the potential to significantly reduce mortality in patients with A. baumannii infections, a life-threatening complication in hospitalized and intensive care patients undergoing anti-infective therapy. OMN6 is highly effective against a wide range of A. baumannii.

“We are very pleased with the progress of our compound,” said Dr. Moshik Cohen-Kutner, CEO of Omnix Medical. “According to the latest estimates published in The Lancet, approximately 5 million deaths are associated with bacterial AMR each year, while available drugs do not sufficiently address the problem of increasing drug resistance. Our goal is to improve the standard of care for life-threatening infections with first-class anti-infectives that take advantage of a natural mechanism of action successfully established in insect immunity.

Dr. Niv Bachnoff, CSO of Omnix Medical, added: “It is time to act. The silent pandemic of antimicrobial resistance is a major global health challenge with ripple effects around the world. “

About Ommix Medical

Omnix Medical was founded in 2015 to meet the urgent need for new, life-saving anti-infective drugs. Omnix’s proprietary technology kills bacteria by mimicking the innate insect immune system which uses unique molecules to effectively and selectively kill resistant bacterial strains without toxic effects. This mechanism kills bacteria on contact, spanned over 200 million years of evolution, and is at the heart of Omnix technology. The company’s lead compound is being developed for the treatment of life-threatening hospital-acquired infections (HIA) and has shown significantly higher potency than currently available antibiotics. More importantly, Omnix technology prevents the development of new resistors to win the war against AMR.

THE SOURCE: Omnix Medical

Comments are closed.